Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kairos Pharma (KAPA) Other Non-Current Assets (2024 - 2025)

Kairos Pharma's Other Non-Current Assets history spans 2 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 20.77% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.1 million, down 20.77%, while the annual FY2025 figure was $1.1 million, 20.77% down from the prior year.
  • Other Non-Current Assets reached $1.1 million in Q4 2025 per KAPA's latest filing, down from $1.7 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $1.7 million in Q1 2025 to a low of $1.1 million in Q4 2025.